Testing and Treatment for Hepatitis C in Patients With HCC

July 13, 2015
Michael Manns, MD

Michael Manns, MD, chairman for the Department of Gastroenterology, Hepatology, and Endocrinology, Center of Internal Medicine, Hanover Medical School, Hanover, Germany, Vice President, United European Gastroenterology (UEG), discusses testing and treatment for Hepatitis C in patients with, as well as without, Hepatocellular carcinoma (HCC) liver cancer.

Manns explains the inefficiency of prior treatments for Hepatitis C and how current treatments could produce less adverse effects and potentially prevent cancer. In the past, treatments lasted as long as one year, but new testing has shown that it can be reduced to as little as 12 weeks. Manns also discusses the information that is needed, in order to continue with testing in the future.

Michael Manns, MD, chairman for the Department of Gastroenterology, Hepatology, and Endocrinology, Center of Internal Medicine, Hanover Medical School, Hanover, Germany, Vice President, United European Gastroenterology (UEG), discusses testing and treatment for Hepatitis C in patients with, as well as without, Hepatocellular carcinoma (HCC) liver cancer.